OncoGenesis was formed to provide women worldwide with access to point-of-care screening for Cervical Cancer. OncoGenesis was launched by the co-founder of St. Jude Medical and sales and marketing Executive at Medtronic.
Cervical cancer is the second most prevalent form of cancer found in women with approximately half a million dying unnecessarily each year. This multi-billion dollar market is the focus of an experienced group of executives, scientists & medical advisors who are developing this breakthrough diagnostic system for use in both the clinical laboratory and point-of-care markets.
OncoGenesis is in advanced development and testing of a low cost test that will provide women worldwide access to screening, significantly improving early detection over the current Pap and adjunctive HPV tests.